急性移植物抗宿主病患者中的巨细胞病毒胃肠炎
该回顾性研究基于日本登记数据库分析3759例发生II-IV级急性移植物抗宿主病的成人患者,发现从aGVHD发生至第365天巨细胞病毒胃肠炎累积发生率为5.7%,高龄、使用霉酚酸酯联合钙调神经磷酸酶抑制剂预防GVHD、下消化道aGVHD及全身性类固醇使用为独立危险因素,CMV胃肠炎与无复发生存死亡率升高相关,来特莫韦预防可降低其发生率和NRM风险。
要点
- II-IV级aGVHD后第365天CMV胃肠炎累积发生率为5.7%。
- 高龄、霉酚酸酯联合钙调神经磷酸酶抑制剂预防、下消化道aGVHD及全身性类固醇使用为独立危险因素。
- 来特莫韦预防可降低CMV胃肠炎发生率(HR 0.50)及无复发生存死亡率风险(HR 0.72)。
核心结论
- CMV胃肠炎是威胁生命的并发症,需要来特莫韦预防策略和目标性监测。
研究设计与样本
- 回顾性分析日本登记数据库中3759例连续成人患者,均为发生II-IV级急性移植物抗宿主病者。
主要发现
- 从II-IV级aGVHD发生至第365天,CMV胃肠炎累积发生率为5.7%。
- 高龄(HR 1.60;95%CI 1.16-2.22;P=.004)、使用霉酚酸酯联合钙调神经磷酸酶抑制剂预防GVHD(HR 1.73;95%CI 1.08-2.77;P=.024)、下消化道aGVHD(HR 2.17;95%CI 1.58-2.98;P<.001)及全身性类固醇使用(HR 1.78;95%CI 1.16-2.74;P=.008)为CMV胃肠炎的独立危险因素。
- 发生CMV胃肠炎与无复发生存死亡率风险升高相关(HR 1.89;95%CI 1.50-2.39;P<.001)。
- 来特莫韦预防显著降低CMV胃肠炎发生率(HR 0.50;95%CI 0.25-0.99;P=.047)及无复发生存死亡率风险(HR 0.72;95%CI 0.52-0.99;P=.043)。
临床怎么用
- 原文结论提出需要来特莫韦预防策略和目标性监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A preemptive strategy has successfully decreased cytomegalovirus (CMV) disease after allogeneic hematopoietic cell transplantation (HCT). However, some recipients still develop CMV gastroenteritis, especially after acute graft-versus-host disease (aGVHD), and its incidence, risk factors, and prognostic impact remain to be elucidated. We retrospectively analyzed 3759 consecutive adult patients who developed grade II-IV aGVHD using a Japanese registry database. The cumulative incidence of CMV gastroenteritis was 5.7% by day 365 from the development of grade II-IV aGVHD. Advanced age (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.16-2.22; P = .004), GVHD prophylaxis with mycophenolate mofetil and calcineurin inhibitor (HR, 1.73; 95% CI, 1.08-2.77; P = .024), lower-gut aGVHD (HR, 2.17; 95% CI, 1.58-2.98; P < .001), and the use of systemic steroids (HR, 1.78; 95% CI, 1.16-2.74; P = .008) were independent risk factors for CMV gastroenteritis. Development of CMV gastroenteritis was associated with an increased risk of nonrelapse mortality (HR, 1.89; 95% CI, 1.50-2.39; P < .001). Moreover, letermovir prophylaxis significantly reduced both the incidence of CMV gastroenteritis (HR, 0.50; 95% CI, 0.25-0.99; P = .047) and the risk of nonrelapse mortality (HR, 0.72; 95% CI, 0.52-0.99; P = .043). In summary, CMV gastroenteritis is a life-threatening complication that sets the need for preventive strategies with letermovir and targeted surveillance.
引用
- Akahoshi Y, Kimura SI, Tada Y, et al. Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. Blood Adv. 2022. PMID: 34788389. doi:10.1182/bloodadvances.2021005885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。